Recently recognized platelet agonists

Current Opinion in Hematology

Volumn 18, Issue 5, 2011, Pages 309-314

  Morrell, Craig N ^a   Maggirwar, Sanjay B ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

agonists; glutamate receptor; inflammation; platelet

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADRENALIN; AMPA RECEPTOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BILE SALT DEPENDENT LIPASE; CD36 ANTIGEN; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CXCR4; COLLAGEN; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; LECTIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PODOPLANIN; PROTEIN CLEC 2; SEROTONIN; STROMAL CELL DERIVED FACTOR 1; THROMBOCYTE RECEPTOR; THROMBOXANE; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION; INFLAMMATION; MEMBRANE DEPOLARIZATION; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOGENESIS;

ANIMALS; BLOOD PLATELETS; COMMUNICABLE DISEASES; GLUTAMIC ACID; HUMANS; INFLAMMATION MEDIATORS; LECTINS, C-TYPE; PLATELET ACTIVATION; SIGNAL TRANSDUCTION;

EID: 80051784159     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283497dfb     Document Type: Review

References (61)

1. Reheman A, Tasneem S, Ni H, Hayward CP. Mice with deleted multimerin 1 and alpha-synuclein genes have impaired platelet adhesion and impaired thrombus formation that is corrected by multimerin 1. Thromb Res 2010;125:e177-e183.
2. Michell AW, Luheshi LM, Barker RA. Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease. Neurosci Lett 2005;381:294-298. (Pubitemid 40719174)
3. Ehrenreich H, Hasselblatt M, Knerlich F, et al. A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain. Proc Natl Acad Sci U S A 2005;102:862-867. (Pubitemid 40282756)
4. Ferrarese C, Zoia C, Pecora N, et al. Reduced platelet glutamate uptake in Parkinson's disease. J Neural Transm 1999;106(7-8):685-692. (Pubitemid 29401356)
5. Morrell CN, Sun H, Ikeda M, et al. Glutamate mediates platelet activation through the AMPA receptor. J Exp Med 2008;205:575-584. (Pubitemid 351439305)
6. Lang PA, Contaldo C, Georgiev P, et al. Aggravation of viral hepatitis by platelet-derived serotonin. Nat Med 2008;14:756-761. (Pubitemid 351951519)
7. Denis MM, Tolley ND, Bunting M, et al. Escaping the nuclear confines: signaldependent premRNA splicing in anucleate platelets. Cell 2005;122:379-391. (Pubitemid 41127140)
8. Giorgi C, Yeo GW, Stone ME, et al. The EJC factor eIF4AIII modulates synaptic strength and neuronal protein expression. Cell 2007;130:179-191. (Pubitemid 47031322)
9. Sun H, Swaim A, Herrera JE, et al. Platelet kainate receptor signaling promotes thrombosis by stimulating cyclooxygenase activation. Circ Res 2009;105:595-603.
10. Hinoi E, Takarada T, Ueshima T, et al. Glutamate signaling in peripheral tissues. Eur J Biochem 2004;271:1-13. (Pubitemid 38122160)
11. Aliprandi A, Longoni M, Stanzani L, et al. Increased plasma glutamate in stroke patients might be linked to altered platelet release and uptake. J Cereb Blood Flow Metab 2005;25:513-519.
12. Vaccaro M, Riva C, Tremolizzo L, et al. Platelet glutamate uptake and release in migraine with and without aura. Cephalalgia 2007;27:35-40. (Pubitemid 46020799)
13. Sun H, Swaim A, Herrera JE, et al. Platelet kainate receptor signaling promotes thrombosis by stimulating cyclooxygenase activation. Circ Res 2009;105:595-603.
14. Morrell CN, Sun H, Ikeda M, et al. Glutamate mediates platelet activation through the AMPA receptor. J Exp Med 2008;205:575-584. (Pubitemid 351439305)
15. Swaim AF, Field DJ, Fox-Talbot K, et al. Platelets contribute to allograft rejection through glutamate receptor signaling. J Immunol 2010;185:6999-7006. In this work we demonstrated that platelet GluR signaling contributes to plasma thromboxane and helps drive T-cell recruitment and skin graft rejection.
16. Malenka RC. Synaptic plasticity and AMPA receptor trafficking. Ann N YAcad Sci 2003;1003:1-11. (Pubitemid 38083041)
17. Malinow R, Malenka RC. AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci 2002;25:103-126. (Pubitemid 34748013)
18. Fukata Y, Tzingounis AV, Trinidad JC, et al. Molecular constituents of neuronal AMPA receptors. J Cell Biol 2005;169:399-404. (Pubitemid 40686690)
19. Bredt DS, Nicoll RA. AMPA receptor trafficking at excitatory synapses. Neuron 2003;40:361-379. (Pubitemid 37244101)
20. Hoogland G, Bos IW, Kupper F, et al. Thrombin-stimulated glutamate uptake in human platelets is predominantly mediated by the glial glutamate transporter EAAT2. Neurochem Int 2005;47:499-506. (Pubitemid 41266880)
21. Zoia C, Cogliati T, Tagliabue E, et al. Glutamate transporters in platelets: EAAT1 decrease in aging and in Alzheimer's disease. Neurobiol Aging 2004;25:149-157. (Pubitemid 38121688)
22. Berk M, Plein H, Belsham B. The specificity of platelet glutamate receptor supersensitivity in psychotic disorders. Life Sci 2000;66:2427-2432. (Pubitemid 30314186)
23. Ben-Chaim Y, Chanda B, Dascal N, et al. Movement of 'gating charge' is coupled to ligand binding in a G-protein-coupled receptor. Nature 2006;444:106-109. (Pubitemid 44684765)
24. Tolhurst G, Vial C, Leon C, et al. Interplay between P2Y (1), P2Y (12), and P2X (1) receptors in the activation of megakaryocyte cation influx currents by ADP: evidence that the primary megakaryocyte represents a fully functional model of platelet P2 receptor signaling. Blood 2005;106:1644-1651. (Pubitemid 41208577)
25. Vial C, Pitt SJ, Roberts J, et al. Lack of evidence for functional ADP-activated human P2X1 receptors supports a role for ATP during hemostasis and thrombosis. Blood 2003;102:3646-3651. (Pubitemid 37409383)
26. Vial C, Rolf MG, Mahaut-Smith MP, Evans RJ. A study of P2X1 receptor function in murine megakaryocytes and human platelets reveals synergy with P2Y receptors. Br J Pharmacol 2002;135:363-372. (Pubitemid 34151168)
27. Martinez-Pinna J, Tolhurst G, Gurung IS, et al. Sensitivity limits for voltage control of P2Y receptor-evoked Ca2+ mobilization in the rat megakaryocyte. J Physiol 2004;555(Pt 1):61-70. (Pubitemid 38313061)
28. El-Husseini AE, Schnell E, Chetkovich DM, et al. PSD-95 involvement in maturation of excitatory synapses. Science 2000;290:1364-1368.
29. Tomita S, Nicoll RA, Bredt DS. PDZ protein interactions regulating glutamate receptor function and plasticity. J Cell Biol 2001;153:F19-24.
30. Riddell DR, Vinogradov DV, Stannard AK, et al. Identification and characterization of LRP8 (apoER2) in human blood platelets. J Lipid Res 1999;40:1925-1930. (Pubitemid 29477264)
31. Pennings MT, Derksen RH, Urbanus RT, et al. Platelets express three different splice variants of ApoER2 that are all involved in signaling. J Thromb Haemost 2007;5:1538-1544. (Pubitemid 46965385)
32. Aslam R, Saeed SA, Ahmed S, Connor JD. Lipoproteins inhibit platelet aggregation and arachidonic acid metabolism in experimental hypercholesterolaemia. Clin Exp Pharmacol Physiol 2008;35(5-6):656-662. (Pubitemid 351490102)
33. Chen LY, Mehta JL. Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets. Life Sci 1994;55:1815-1821.
34. Podrez EA, Byzova TV, Febbraio M, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 2007;13:1086-1095. (Pubitemid 47517507)
35. Chen K, Febbraio M, Li W, Silverstein RL. A specific CD36-dependent signaling pathway is required for platelet activation by oxidized low-density lipoprotein. Circ Res 2008;102:1512-1519.
36. Ghosh A, Murugesan G, Chen K, et al. Platelet CD36 surface expression levels affect functional responses to oxidized LDL and are associated with inheritance of specific genetic polymorphisms. Blood 2011;117:6355-6366.
37. Suzuki-Inoue K, Fuller GL, Garcia A, et al. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood 2006;107:542-549. (Pubitemid 43076377)
38. Bertozzi CC, Hess PR, Kahn ML. Platelets: covert regulators of lymphatic development. Arterioscler Thromb Vasc Biol 2010;30:2368-2371.
39. Bertozzi CC, Schmaier AA, Mericko P, et al. Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. Blood 2010;116:661-670. This article is unique in that it assigns an important mechanistic role for platelets in a develompmental process in which platelets were never thought to have a functional role.
40. Suzuki-Inoue K, Inoue O, Ding G, et al. Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem 2010;285:24494-24507. The generation of this knockout mouse has helped to clarify some of the roles for CLEC-2 in thombus formation and will be important for future studies.
41. Chaipan C, Soilleux EJ, Simpson P, et al. DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets. J Virol 2006;80:8951-8960. (Pubitemid 44359969)
42. Abi-Younes S, Si-Tahar M, Luster AD. The CC chemokines MDC and TARC induce platelet activation via CCR4. Thromb Res 2001;101:279-289. (Pubitemid 32206583)
43. Kowalska MA, Ratajczak MZ, Majka M, et al. Stromal cell-derived factor-1 and macrophage-derived chemokine: 2 chemokines that activate platelets. Blood 2000;96:50-57. (Pubitemid 30456449)
44. Kowalska MA, Ratajczak J, Hoxie J, et al. Megakaryocyte precursors, megakaryocytes and platelets express the HIV co-receptor CXCR4 on their surface: determination of response to stromal-derived factor-1 by megakaryocytes and platelets. Br J Haematol 1999;104:220-229. (Pubitemid 29083327)
45. Panicot-Dubois L, Thomas GM, Furie BC, et al. Bile salt-dependent lipase interacts with platelet CXCR4 and modulates thrombus formation in mice and humans. J Clin Invest 2007;117:3708-3719. (Pubitemid 350224082)
46. Bruneau N, Bendayan M, Gingras D, et al. Circulating bile salt-dependent lipase originates from the pancreas via intestinal transcytosis. Gastroenterology 2003;124:470-480. (Pubitemid 36169263)
47. Caillol N, Pasqualini E, Mas E, et al. Pancreatic bile salt-dependent lipase activity in serum of normolipidemic patients. Lipids 1997;32:1147-1153. (Pubitemid 27508106)
48. Srivastava K, Cockburn IA, Swaim A, et al. Platelet factor 4 mediates inflammation in experimental cerebral malaria. Cell Host Microbe 2008;4:179-187.
49. Crum-Cianflone NF, Weekes J, Bavaro M. Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era. AIDS Patient Care STDS 2008;22:771-778.
50. Lijfering WM, Ten Kate MK, Sprenger HG, van der Meer J. Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy. J Thromb Haemost 2006;4:1928-1930. (Pubitemid 44226770)
51. Satchell CS, Cotter AG, O'Connor EF, et al. Platelet function and HIV: a casecontrol study. AIDS 2010;24:649-657.
52. Wolf K, Tsakiris DA, Weber R, et al. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002;185:456-462. (Pubitemid 34142807)
53. Khovidhunkit W, Memon RA, Shigenaga JK, et al. Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Metabolism 1999;48:1524-1531.
54. Corrales-Medina VF, Simkins J, Chirinos JA, et al. Increased levels of platelet microparticles in HIV-infected patients with good response to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2010;54:217-218.
55. Wachtman LM, Skolasky RL, Tarwater PM, et al. Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus-associated dementia. Arch Neurol 2007;64:1264-1272. (Pubitemid 47403080)
56. Cognasse F, Hamzeh-Cognasse H, Berthet J, et al. Altered release of regulated upon activation, normal T-cell expressed and secreted protein from human, normal platelets: contribution of distinct HIV-1MN gp41 peptides. AIDS 2009;23:2057-2059.
57. Rozmyslowicz T, Majka M, Kijowski J, et al. Platelet-and megakaryocytederived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV. AIDS 2003;17:33-42. (Pubitemid 36106296)
58. Youssefian T, Drouin A, Masse JM, et al. Host defense role of platelets: engulfment of HIV and Staphylococcusaureus occurs inaspecific subcellular compartment and is enhanced by platelet activation. Blood 2002;99:4021-4029. (Pubitemid 35332043)
59. Zhang W, Dang S, Wang J, et al. Specific cross-reaction of antidsDNA antibody with platelet integrin GPIIIa49-66. Autoimmunity 2010;43:682-689.
60. Davidson DC, Hirschman MP, Spinelli SL, et al. Antiplatelet activity of valproic acid contributes to decreased soluble CD40 ligand production in HIV type 1-infected individuals. J Immunol 2011;186:584-591.
61. Sui Z, Sniderhan LF, Schifitto G, et al. Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia. J Immunol 2007;178:3226-3236. (Pubitemid 46333205)